ChiCTR2400083084: Pharmacokinetics and Safety of Insulin Degludec/Insulin Aspart Injection with the Ryzodeg Produced by Novo Nordisk in Healthy Chinese Subjects: A phase I, Randomized, Open-label, Single-dose, Two-phase, Crossover study |
|
|
| Completed | 1 | 32 | | Phase 1: Injection of insulin degludec/insulin aspart developed by Hui Sheng Bio-pharmaceutical; Phase 2: Injection of Ryzodeg produced by Novo Nordisk; Phase 1: Injection of Ryzodeg produced by Novo Nordisk; Phase 2: Injection of insulin degludec/insulin aspart developed by Hui Sheng Bio-pharmaceutical | West China Hospital, Sichuan University; Hui Sheng Bio-pharmaceutical Co., Ltd., Sponsor | Type 2 Diabetes Mellitus | | | | |
